Efficacy and safety of preoperative somatostatine analogue treatment in acromegaly

Efficacy and safety of preoperative somatostatine analogue treatment in acromegaly - Efficacy and safety of preoperative somatostatine analogue treatment in acromegaly

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000015518

Enrollment

Registered

2014-10-24

Start date

2014-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acromegaly

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients who have been diagnosed with acromegaly 2) Patients with surgical indications of pituitary tumor 3) Patients who informed consent document

Exclusion criteria

Exclusion criteria: 1) Patients with severe infections, liver disease, kidney disease, etc. 2) Patient who cannot be performed the necessary examination for evaluation. 3) Patients who investigator deem inappropriate.

Design outcomes

Primary

Measure	Time frame
Cure rate of postoperative IGF-1 level	—

Countries

Japan

Contacts

Public ContactKohei Yamamoto

Hokkaido University Division of Rheumatology, Endocrinology and Nephrology

kohei2031@gmail.com011-716-5915

Outcome results